About Eligard

Efficacy

ELIGARD®* (leuprorelin acetate) provides T suppression ≤20 ng/dL in most patients1-3

Patients who achieved T suppression (≤20 ng/dL) with ELIGARD® 45 mg 6-month formulation (n=111)3

References+

  • 1. Perez-Marreno R, et al. Clin Ther 2002; 24: 1902-14.
  • 2. Chu FM, et al. J Urol. 2002; 168: 1199-203.
  • 3. Crawford ED, et al. J Urol. 2006; 175: 533-6.
  • 4. Eligard® 45mg Summary of Product Characteristics.

ELIGARD® 45 mg 6-month formulation

*1-, 3- and 6-month ELIGARD® formulations.
SEM = standard error of mean; T = testosterone

References+

  • 1. Perez-Marreno R, et al. Clin Ther 2002; 24: 1902-14.
  • 2. Chu FM, et al. J Urol. 2002; 168: 1199-203.
  • 3. Crawford ED, et al. J Urol. 2006; 175: 533-6

The main aim of ADT is to reduce serum T levels to those seen after bilateral orchidectomy1

ADT = androgen deprivation therapy; EAU = European Association of Urology; T = testosterone.

References+

  • 1. Mottet N, et al. EAU - EANM - ESTRO - ESUR - SIOG guidelines on prostate cancer. 2023. Available at: https://uroweb.org/guidelines/prostate-cancer. Last accessed: 23 March 2023.
  • 2. Crawford ED, et al. J Urol. 2021; 205: 554-560.

The advantages of T <20 ng/dL

Better results are consistently seen with T levels <50 ng/dL1

Maintaining T levels <20 ng/dL is associated with:

The longest time to progression in metastatic disease2

Improvement in duration of response and time to CRPC3

Improved biochemical relapse-free survival4

Lower rate of biochemical recurrence*5

*Biochemical recurrence was defined as a PSA level ≥ the 2-year nadir PSA + 2 ng/mL.5
CRPC = castration-resistant prostate cancer; PSA = prostate-specific antigen; T = testosterone.

References+

  • 1. Mottet N, et al. EAU - EANM - ESTRO - ESUR - SIOG guidelines on prostate cancer. 2023. Available at: https://uroweb.org/guidelines/prostate-cancer. Last accessed: 23 March 2023.
  • 2. Bertaglia V, et al. Clin Genitourin Cancer 2013; 11(3): 325-30.
  • 3. Klotz L, et al. J Clin Oncol 2015; 33: 1151-6.
  • 4. Ozyigit G, et al. World J Clin Oncol 2019; 10(8): 283-92.
  • 5. Bryant AK, et al. Int J Radiat Oncol Biol Phys 2019; 103(5): 1068-76.

Effective T suppression: what is the reality?

Patients failing to achieve T suppression <20 ng/dL1

Up to 0%

About 13-38% of men treated with an LHRH analogue fail to achieve T levels <20 ng/dL1. Up to 24% experience T surges >50 ng/dL during long-term treatment1
LHRH = luteinizing hormone releasing hormone; T = testosterone.

References+

  • 1. Mottet N, et al. EAU - EANM - ESTRO - ESUR - SIOG guidelines on prostate cancer. 2023. Available at: https://uroweb.org/guidelines/prostate-cancer. Last accessed: 23 March 2023.

ELIGARD®* (leuprorelin acetate) provides T suppression ≤20 ng/dL in most patients1-3

ELIGARD® 45 mg 6-month formulation

Please refer to the Summary of Product Characteristics of Eligard for additional information.

References+

  • 1. Perez-Marreno R, et al. Clin Ther 2002; 24: 1902-14.
  • 2. Chu FM, et al. J Urol 2002; 168: 1199-203.
  • 3. Crawford ED, et al. J Urol. 2006; 175: 533-6